Tech Company Financing Transactions
Hemispherian Funding Round
Hemispherian closed a $9.8 million financing round on 10/19/2022. Backers included European Innovation Council Fund.
Transaction Overview
Company Name
Announced On
10/19/2022
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$9,800,000
Round
Undisclosed
Investors
Proceeds Purpose
Financing from the EIC accelerator will be used to advance GLIX1, one of Hemispherian's lead assets, through a phase I and phase II clinical trial.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Gaustadalléen 21
Oslo, 0349
Norway
Oslo, 0349
Norway
Phone
Website
Email Address
Overview
Hemispherian is an innovative preclinical pharmaceutical company focused on developing a novel class of small molecule drugs. These drugs target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers. The Company's lead compound is currently in late stage preclinical development for glioblastoma multiforme, a deadly cancer of the central nervous system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Zeno Albisser
Chief Operating Officer
Terezia Prikrylova
Chief Scientific Officer
Adam Robertson
Browse more venture capital transactions:
Prev: 10/19/2022: BlueSkeye AI venture capital transaction
Next: 10/19/2022: TSOLife venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs